Legend Biotech’s clinical trial of the company’s candidate drug for relapsed or refractory T-cell lymphoma was placed on hold effective February 11 after some issues were raised on the first patient dosed. 

A study published in the scientific journal Nature explains why certain kinds of cancer cells often spread to the lymph nodes before various organs within the body.

GentiBio closed on a $20 million seed funding led by OrbiMed, Novartis Venture Fund and RA Capital Management. The company also announced exclusive licensing partnerships with Seattle Children’s Research Institute, Benaroya Research Institute at Virginia Mason (BRK), and MIGAL Galilee Research Institute (MIGAL).